[Treatment for central nervous system vasculitis].
Masaya Honda1, Michiaki Koga, Takashi Kanda
1Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|April 8, 2015
Summary
Primary central nervous system (CNS) vasculitis is a rare, idiopathic disorder affecting the brain and spinal cord. Current treatments, often based on other vasculitides, include corticosteroids and cyclophosphamide, with novel options like rituximab being explored for refractory cases.
Area of Science:
- Neurology
- Immunology
- Rheumatology
Context:
- Central nervous system (CNS) vasculitis is categorized as primary or secondary.
- Primary CNS vasculitis is a rare disorder affecting only the brain and spinal cord, with an unknown cause.
- No randomized clinical trials exist for primary CNS vasculitis treatment.
Purpose:
- To review current treatment strategies for primary CNS vasculitis.
- To highlight the importance of early detection and treatment.
- To discuss potential novel therapeutic options for refractory cases.
Summary:
- Treatment for primary CNS vasculitis relies on strategies from other vasculitides, primarily corticosteroids with or without cyclophosphamide.
- Early diagnosis and intervention are crucial for preventing severe outcomes.
- For patients unresponsive or intolerant to standard therapy, alternative immunosuppressants like mycophenolate mofetil, TNF-α blockers, and rituximab are considered.
Impact:
- Timely corticosteroid treatment can lead to favorable responses and prevent serious complications.
- The development of new treatments is essential for patients with refractory primary CNS vasculitis.
- Exploring novel immunosuppressive agents offers hope for improved management of this rare neurological condition.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
621
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
621
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
574
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
574
01:16Vascular Spasm
5.0K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
5.0K
01:14Myocarditis III: Medical Management
330
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
330